eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing
eXoZymes (NASDAQ:EXOZ) has been selected as a core industry partner in the $9.2 million NSF-funded Meta-PURE initiative, led by Georgia Tech. The company will receive a $3 million share of the total funding to develop a cell-free ATP-generating module that will serve as a power source for various chemical production processes.
As the key industrial partner, eXoZymes will focus on creating a standardized, plug-and-play cell-free power plant system that enables faster reaction times and greater product yields. The company will also develop a production module for santalene, a high-value fragrance compound used in aromatherapy and traditional medicine.
eXoZymes (NASDAQ:EXOZ) è stata selezionata come partner industriale principale nell'iniziativa Meta-PURE da 9,2 milioni di dollari finanziata dalla NSF, guidata da Georgia Tech. L'azienda riceverà una quota di 3 milioni di dollari del finanziamento totale per sviluppare un modulo generatore di ATP senza cellule che fungerà da fonte di energia per vari processi di produzione chimica.
Come partner industriale chiave, eXoZymes si concentrerà sulla creazione di un sistema standardizzato e plug-and-play di centrale energetica senza cellule che consenta tempi di reazione più rapidi e rese di prodotto maggiori. L'azienda svilupperà inoltre un modulo di produzione per la santalene, un composto profumato di alto valore utilizzato in aromaterapia e medicina tradizionale.
eXoZymes (NASDAQ:EXOZ) ha sido seleccionada como socio industrial principal en la iniciativa Meta-PURE financiada por la NSF con 9,2 millones de dólares, liderada por Georgia Tech. La empresa recibirá una parte de 3 millones de dólares del financiamiento total para desarrollar un módulo generador de ATP sin células que servirá como fuente de energía para diversos procesos de producción química.
Como socio industrial clave, eXoZymes se enfocará en crear un sistema estandarizado y plug-and-play de planta energética sin células que permita tiempos de reacción más rápidos y mayores rendimientos de producto. La compañía también desarrollará un módulo de producción para la santaleno, un compuesto aromático de alto valor utilizado en aromaterapia y medicina tradicional.
eXoZymes (NASDAQ:EXOZ)는 조지아 공대가 주도하는 미국 NSF가 920만 달러를 지원하는 Meta-PURE 사업의 핵심 산업 파트너로 선정되었습니다. 회사는 총 자금 중 300만 달러를 받아 다양한 화학 생산 공정에 동력을 공급할 무세포 ATP 생성 모듈을 개발할 예정입니다.
주요 산업 파트너로서 eXoZymes는 반응 속도를 높이고 제품 수율을 향상시키는 표준화된 플러그 앤 플레이 무세포 발전 시스템을 만드는 데 집중할 것입니다. 또한 아로마테라피와 전통 의학에 사용되는 고부가가치 향료 화합물인 산탈렌 생산 모듈도 개발할 계획입니다.
eXoZymes (NASDAQ:EXOZ) a été sélectionnée comme partenaire industriel principal dans l'initiative Meta-PURE financée par la NSF à hauteur de 9,2 millions de dollars, dirigée par Georgia Tech. L'entreprise recevra une part de 3 millions de dollars du financement total pour développer un module générateur d'ATP sans cellules qui servira de source d'énergie pour divers processus de production chimique.
En tant que partenaire industriel clé, eXoZymes se concentrera sur la création d'un système standardisé et plug-and-play de centrale énergétique sans cellules, permettant des temps de réaction plus rapides et des rendements de produits supérieurs. L'entreprise développera également un module de production pour la santalène, un composé parfumé de grande valeur utilisé en aromathérapie et en médecine traditionnelle.
eXoZymes (NASDAQ:EXOZ) wurde als Kernindustripartner in der von Georgia Tech geleiteten Meta-PURE-Initiative mit einer Finanzierung von 9,2 Millionen US-Dollar durch die NSF ausgewählt. Das Unternehmen erhält einen 3-Millionen-Dollar-Anteil der Gesamtfinanzierung, um ein zellfreies ATP-Generatormodul zu entwickeln, das als Energiequelle für verschiedene chemische Produktionsprozesse dient.
Als wichtiger Industriepartner wird sich eXoZymes darauf konzentrieren, ein standardisiertes, Plug-and-Play-zellfreies Kraftwerkssystem zu schaffen, das schnellere Reaktionszeiten und höhere Produktausbeuten ermöglicht. Das Unternehmen wird zudem ein Produktionsmodul für Santalene entwickeln, eine hochwertige Duftstoffverbindung, die in Aromatherapie und traditioneller Medizin verwendet wird.
- Secured $3 million funding as part of a $9.2M NSF initiative
- Selected as key industrial partner in prestigious research coalition
- Development of high-value santalene production module expands market opportunities
- Technology enables faster reaction times and greater product yields
- None.
Insights
eXoZymes secured $3M in NSF funding to develop cell-free enzyme systems with potential applications across multiple high-value markets.
This
The technical approach here is quite innovative. By decoupling the energy-generating system (ATP production) from the actual chemical synthesis modules, eXoZymes is addressing one of the fundamental challenges in cell-free biomanufacturing - maintaining sufficient energy levels to drive complex enzymatic reactions. This modular approach could potentially overcome efficiency barriers that have limited industrial application of cell-free systems.
Their initial commercial target of santalene is strategically chosen. This fragrance compound commands premium pricing in the market and currently relies on extraction from sandalwood, which faces sustainability challenges. The mention of pharmaceutical applications for santalene derivatives suggests potential future high-value markets beyond fragrances.
From a technical perspective, the emphasis on compatibility with both purified and lysate-based systems indicates eXoZymes is developing a versatile platform that could work across different cell-free formats, maximizing potential applications. This grant provides both financial resources and institutional partnerships to advance their enzyme engineering capabilities in a framework that appears designed for practical, scalable applications.
MONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its role in the Meta-PURE initiative, a
Led by Georgia Tech with a coalition of top academic and industry groups, Meta-PURE will build a suite of standardized, interoperable 'modules' for cell-free biomanufacturing, enabling plug-and-play modules that can rapidly shift between use cases - from high-value nutraceuticals, to essential chemicals or pharmaceuticals. eXoZymes' contribution builds on its proven ability to design complex enzyme cascades that operate outside of cells at unprecedented yields.
"Our job in Meta-PURE is to build a cell-free power plant - an ATP-generating module that other teams can plug into to drive their own production modules," said Dr. Paul Opgenorth, co-founder of eXoZymes and co-principal investigator on the award. Dr. Opgenorth continues, "By decoupling the power module from the production module, we're enabling faster reaction times, greater product yields, and making the development of production modules more accessible for our partners across a broad spectrum of synthetic biology applications."
For Meta-PURE, eXoZymes - formerly known as Invizyne Technologies - will serve as the key industrial partner, with a
In addition, eXoZymes' role also includes developing a production module for santalene, an extremely high-value fragrance compound, traditionally extracted from sandalwood for use in aromatherapy and traditional medicine formulations. Furthermore, derivates of santalene have been investigated in pharmaceutical use cases.
Other coalition partners will develop targets spanning a wide range of complexity and markets, but all relying on eXoZymes' plug-and-play cell-free power plant, which will be tested and optimized to both purified and lysate-based exozymes biosolutions to ensure compatibility and performance.
About the Meta-PURE Initiative
Meta-PURE is part of NSF Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (CFIRE) program and supported under Cooperative Agreement No. 2452482. It is designed to lay foundational infrastructure for a flexible, cost-effective, and robust U.S. bioeconomy. Work under this program will commence on July 1, 2025 and will run for three years.
Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the U.S. National Science Foundation.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce chemical compounds, enabling the company's partners to replace traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more on exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
SOURCE: eXoZymes
View the original press release on ACCESS Newswire
FAQ
What is eXoZymes' (NASDAQ:EXOZ) role in the Meta-PURE initiative?
How much funding did eXoZymes (EXOZ) receive from the NSF grant?
What products will eXoZymes (EXOZ) develop through the Meta-PURE project?
What are the benefits of eXoZymes' cell-free power plant technology?
What is the market potential for eXoZymes' santalene production?
